Tempus AI, an artificial intelligence-driven precision medicine company, has completed its acquisition of Ambry Genetics, a genetic testing company focused on improving health by understanding the relationship between genetics and disease. The deal, valued at USD 600 million, includes USD 375 million in cash and USD 225 million in shares, with USD 100 million subject to a one-year lock-up. Financing was provided by Ares Management Credit Funds.
Also Read: Corti Launches Specialised AI Models for Healthcare
Tempus AI Acquires Ambry Genetics
The acquisition strengthens Tempus' ability to integrate AI-powered analytics with genetic testing, enhancing diagnostics and patient care. Ambry Genetics will continue operating as a wholly-owned subsidiary under its current leadership, Tempus announced on Monday.
"This acquisition complements our strategy of leveraging diagnostics and data to drive innovation, further strengthening our ability to deliver cutting-edge solutions to clinicians, patients, and life sciences companies," said Eric Lefkofsky, Founder and CEO of Tempus.
Also Read: Meta Says Open-Source AI Is Transforming Healthcare Outcomes
Tempus AI Abilities
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data and an operating system to make that data accessible and useful, Tempus says it provides AI-enabled precision medicine solutions to physicians to deliver personalised patient care while facilitating the discovery, development and delivery of optimal therapeutics.
